Showing 5 results
-
Media Release /The Scottish Medicines Consortium (SMC) announced today that they have accepted Kisqali (ribociclib) for use within NHS Scotland as an adjuvant treatment option in combination with an aromatase…
-
Media Release /Spinal muscular atrophy (SMA) is one of the leading genetic causes of infant death in the UK.1,2Diagnosing and treating SMA at the earliest possible point provides the strongest opportunity to help…
-
Media Release /The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending ribociclib, within its marketing authorisation, as an adjuvant treatment option to be used…
-
Media Release /Today, the National Institute for Health and Care Excellence (NICE) published its preliminary optimised recommendation1 for ribociclib to be used as adjuvant treatment in combination with an…
-
Media Release /The Medicines and Healthcare products Regulatory Agency (MHRA) have authorised a new indication for ribociclib as an adjuvant treatment option to be used in combination with an aromatase inhibitor (…
